Privia Health to Report First Quarter 2026 Results on Thursday, May 7

ARLINGTON, Va., April 08, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its first quarter ended March 31, 2026 before market open on Thursday, May 7, 2026.

GlobeNewsWire • Apr 8, 2026

Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence

ARLINGTON, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated medical groups, collectively Privia Medical Group, has been named a recipient of the 2026 MAP (Measure, Apply, Perform) Award for High Performance in Revenue Cycle, sponsored by the Healthcare Financial Management Association (HFMA).

GlobeNewsWire • Mar 24, 2026

Privia Health Group CFO Sells $283,000 Worth of Shares to Cover Taxes

Privia Health's CFO sold 13,018 direct shares for approximately $283,000 over two days, at an average price of $21.71 per share. The sale represented 5.24% of the CFO's total direct holdings as of the transaction dates.

The Motley Fool • Mar 22, 2026

Wall Street Analysts See a 43.44% Upside in Privia Health (PRVA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 43.4% in Privia Health (PRVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Mar 18, 2026

Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rat.

Business Wire • Mar 3, 2026

Wall Street Analysts Think Privia Health (PRVA) Could Surge 25.45%: Read This Before Placing a Bet

The mean of analysts' price targets for Privia Health (PRVA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Feb 27, 2026

Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript

Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results

All 2025 Operating and Financial Metrics At or Above High End of Guidance Ranges Full-year 2025 Net Income +59.3% from 2024 Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024 Full-year 2025 Net Cash Provided by Operating Activities of $163.4 Million , +49.5% from 2024; Year-end 2025 Cash Balance of $479.7 Million and No Debt 2026 Guidance Reflects ~20% Adjusted EBITDA Growth at Midpoint ARLINGTON, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and operating results for the fourth quarter and full year ended December 31, 2025.

GlobeNewsWire • Feb 26, 2026

Privia Health (PRVA) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Feb 26, 2026

Privia Health (PRVA) Q4 Earnings and Revenues Beat Estimates

Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.03 per share a year ago.

Zacks Investment Research • Feb 26, 2026